Apricus Biosciences Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: oldcoach19 who wrote (1486)	9/10/2015 8:55:16 AM
From: eico20	Read Replies (2) of 2026

wow old coach, that's huge news, License Agreement With Allergan for the U.S. Rights to Vitaros(TM)Apricus to Lead Clinical and Regulatory Efforts; Allergan Retains Commercialization Option in U.S. SAN DIEGO, Sept. 10, 2015 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq: APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has licensed the U.S. development and commercialization rights for Vitaros™ from Allergan. Under the license agreement, Apricus will be responsible for all Vitaros development efforts in the United States. Upon the Food and Drug Administration's ("FDA") acceptance of a New Drug Application ("NDA") for Vitaros, Allergan may elect to exercise its one time opt-in right to assume all future marketing and selling activities in the United States in exchange for certain financial considerations.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next